Document Detail


Antithrombotic therapies for stroke prevention in atrial fibrillation.
MedLine Citation:
PMID:  15194994     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Atrial fibrillation (AF) is now regarded as the arrhythmia for which patients are hospitalized the most frequently, an arrhythmia that is responsible for significant morbidity and mortality. Of particular importance is that the arrhythmia is associated with a significant incidence of thromboembolism which may induce disabling and incapacitating strokes, sometimes fatal. In the past, it was thought that in patients with AF restoration and maintenance of sinus rhythm prevent the development of strokes, a presumption that has not been vindicated by controlled clinical trials. On the other hand, over many decades, it has been established that appropriate anticoagulation especially with warfarin can reduce stroke rate in nonvalvular AF by about 70%, and mortality by 26%. Aspirin reduces stroke rate by 26%, mortality by about 10%. Thus, in AF oral anticoagulants have become the focal point of therapy for the prevention of strokes and the safety and efficacy of such a therapy has been established by controlled clinical trials; moreover, the subsets of patients with AF in whom anticoagulation is mandatory have been defined on the basis of defined risk factors. Warfarin is now the anticoagulant of choice although its limitations are considerable in terms of drug-drug interactions, narrow range of therapeutic index requiring strict monitoring of intensity of anticoagulation, among other limitations which influence compliance of therapy with the agent. In this review, the continuing role of warfarin in the prevention of stroke in patients with AF is discussed as a background for the development of newer anticoagulants. The issue is of particular importance in the older patients, in whom the development of safer antithrombotic therapies remain a major challenge. In this context, the potential role of the direct thrombin inhibitors hold promise for the future and the evolving data on leading compounds of this class which may be competitive with warfarin are discussed.
Authors:
C Economides Muñoz; B N Singh
Related Documents :
17675614 - Predictive factors, morphologic effects, and proposed treatment paradigm for type ii en...
19763194 - The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review o...
15367514 - Plasma von willebrand factor, soluble thrombomodulin, and fibrin d-dimer concentrations...
12685134 - Three-dimensional reconstruction of pulmonary veins in patients with atrial fibrillatio...
1800874 - The laryngeal mask airway--clinical experience.
2883804 - Voluntary movement dysfunction in huntington's disease and tardive dyskinesia.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  52     ISSN:  0026-4725     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-06-14     Completed Date:  2004-07-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  125-39     Citation Subset:  IM    
Affiliation:
Department of Medicine, The Greater Los Angeles Veterans Affairs, Medical Center Healthcare Systems, West Los Angeles Medical Center, Los Angeles, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Ambulatory Care Facilities
Anticoagulants / adverse effects,  therapeutic use*
Aspirin / adverse effects,  therapeutic use
Atrial Fibrillation / blood,  complications*,  epidemiology,  therapy
Azetidines / therapeutic use
Benzylamines
Cerebral Hemorrhage / chemically induced
Drug Design
Factor Xa / antagonists & inhibitors
Fibrinolytic Agents / therapeutic use*
Humans
Prospective Studies
Randomized Controlled Trials as Topic
Risk Factors
Self Care
Stroke / epidemiology,  etiology,  prevention & control*
Thrombin / antagonists & inhibitors
Warfarin / adverse effects,  therapeutic use
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Azetidines; 0/Benzylamines; 0/Fibrinolytic Agents; 0/ximelagatran; 50-78-2/Aspirin; 81-81-2/Warfarin; EC 3.4.21.5/Thrombin; EC 3.4.21.6/Factor Xa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Atrial fibrillation and cardioembolic stroke.
Next Document:  The role of pacemaker and defibrillator therapy for the treatment of atrial fibrillation.